These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34544102)

  • 1. Dasiglucagon (Zegalogue) for severe hypoglycemia.
    Med Lett Drugs Ther; 2021 Aug; 63(1631):132-134. PubMed ID: 34544102
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon nasal powder (Baqsimi) for severe hypoglycemia.
    Med Lett Drugs Ther; 2019 Sep; 61(1581):148-149. PubMed ID: 31599866
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
    Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
    Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In brief: A new glucagon injection (Gvoke) for severe hypoglycemia.
    Med Lett Drugs Ther; 2019 Nov; 61(1585):186. PubMed ID: 31770360
    [No Abstract]   [Full Text] [Related]  

  • 5. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
    Battelino T; Tehranchi R; Bailey T; Dovc K; Melgaard A; Yager Stone J; Woerner S; von dem Berge T; DiMeglio L; Danne T
    Pediatr Diabetes; 2021 Aug; 22(5):734-741. PubMed ID: 33934456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasiglucagon: an effective medicine for severe hypoglycemia.
    Xu B; Tang G; Chen Z
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1783-1790. PubMed ID: 34223944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasiglucagon: First Approval.
    Blair HA
    Drugs; 2021 Jun; 81(9):1115-1120. PubMed ID: 34047955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
    Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.
    Li S; Hu Y; Tan X; Wang D; Hu J; Zou P; Wang L
    Expert Opin Pharmacother; 2020 Aug; 21(11):1311-1318. PubMed ID: 32267182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
    Pieber TR; Aronson R; Hövelmann U; Willard J; Plum-Mörschel L; Knudsen KM; Bandak B; Tehranchi R
    Diabetes Care; 2021 Jun; 44(6):1361-1367. PubMed ID: 35239971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal glucagon: a promising approach for treatment of severe hypoglycemia.
    Pontiroli AE
    J Diabetes Sci Technol; 2015 Jan; 9(1):38-43. PubMed ID: 25385946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.
    Wendt SL; Ranjan A; Møller JK; Schmidt S; Knudsen CB; Holst JJ; Madsbad S; Madsen H; Nørgaard K; Jørgensen JB
    J Diabetes Sci Technol; 2017 Nov; 11(6):1101-1111. PubMed ID: 28654314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes.
    Pieber TR; Ajala O; Steen O; Dahl D; Hansen LE; Tehranchi R
    Diabetes Technol Ther; 2021 Nov; 23(11):773-776. PubMed ID: 34252289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
    La Sala L; Pontiroli AE
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasiglucagon for treating severe hypoglycemia in patients with diabetes.
    Ju Y; Zhang D; Yang J
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):799-803. PubMed ID: 35848442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia.
    Pontiroli AE; Tagliabue E
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31349701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons.
    Pontiroli AE; Rizzo M; Tagliabue E
    Diabetol Metab Syndr; 2022 Dec; 14(1):193. PubMed ID: 36550552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
    Bailey TS; Willard J; Klaff LJ; Yager Stone J; Melgaard A; Tehranchi R
    Diabetes Obes Metab; 2021 Oct; 23(10):2329-2335. PubMed ID: 34169625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasiglucagon: A Novel Ready-to-Use Treatment for Severe Hypoglycemia.
    Goodhart AL
    Ann Pharmacother; 2023 Mar; 57(3):300-305. PubMed ID: 35861467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Glucagon for Severe Hypoglycemia.
    Grant JS; Graven LJ
    Home Healthc Now; 2017 Feb; 35(2):114-115. PubMed ID: 28157777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.